ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0195

Acceptance of Virtual Reality for Managing Their Disease Among People with Rheumatologic Conditions with and Without Prior Experience Using Virtual Reality

Jeffrey Curtis1, Kimberly Garza2, Cassie Clinton3, Heqin Yang2, Alexicia Richardson2, Cheryl Seals2, Gary Hawkins2, Chad Rose2, William Benjamin Nowell4, Kelly Gavigan5 and Liana Fraenkel6, 1Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Auburn University, Auburn, AL, 3University of Alabama at Birmingham, Hoover, AL, 4Global Healthy Living Foundation, Nyack, NY, 5Global Healthy Living Foundation, Upper Nyack, NY, 6Berkshire Medical Center, Lenox, MA

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, Health Services Research, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Patient Outcomes, Preferences, and Attitudes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: We aimed to assess enthusiasm for the use of virtual reality (VR) for clinical and educational use among people with rheumatologic diseases, comparing those with prior experience using VR to those with no prior experience.

Methods: A cross-sectional, online survey was conducted among adults with rheumatologic conditions who are members of ArthritisPower, an online patient-powered research network (registry). The Technology Acceptance Model was used as a conceptual framework, proposing perceived usefulness of, attitudes toward, and intention to use technology as factors that affect user acceptance. Survey items included prior experience with VR, perceived usefulness and potential enjoyment of using VR, and willingness to use VR to learn how rheumatologic conditions affect the body and what daily life might be like in more advanced stages of disease. Descriptive statistics and Pearson’s chi square were used to compare perceived usefulness, enjoyment, and willingness to use VR in people with and without prior VR experience.

Results: A total of 523 individuals completed the survey. Mean age was 59.4 (SD=11.1) years. Most were female (86.6%) and White (88.3%). The most commonly reported conditions were rheumatoid arthritis (59.7%) and osteoarthritis (53.9%), and the majority (52.4%) had been diagnosed in the last 10 years. Frequencies of perceptions are shown in Table 1. Few participants reported having prior experience using VR (16.3%). Of these, the majority thought they could learn useful information about their condition using VR. A small percentage did not think it would be useful. In contrast, about one-third of respondents who had never used VR thought it would be useful, while the majority were unsure. Three-fourths of respondents who had prior experience using VR reported that they thought they would enjoy using it for this purpose, while only half of the respondents with no prior experience using VR thought they might enjoy using it. Nearly all respondents expressed willingness to use VR to manage their disease, regardless of prior experience using VR. The most commonly endorsed uses of VR included for exercise (77.8%), for physical therapy (73.8%), and for education (61.8%).

Conclusion: Even among people with no prior experience with virtual reality, people with rheumatologic conditions are enthusiastic about using VR to manage their disease state, particularly those with prior experience using VR. Interventions that introduce VR to this patient population for use in learning about and managing their disease are likely to be accepted.

Supporting image 1


Disclosures: J. Curtis, Amgen, Bristol-Myers Squibb (BMS), CorEvitas, IlluminationHealth, Janssen, Lilly, Myriad, Novartis, Pfizer, Sanofi, UCB, Aqtual, Bendcare, FASTER, GlaxoSmithKlein (GSK), Labcorp, Scipher, Setpoint, United Rheumatology, AbbVie, ArthritisPower; K. Garza, None; C. Clinton, None; H. Yang, None; A. Richardson, None; C. Seals, None; G. Hawkins, None; C. Rose, None; W. Nowell, Global Healthy Living Foundation, AbbVie Inc., Amgen, Eli Lilly; K. Gavigan, None; L. Fraenkel, None.

To cite this abstract in AMA style:

Curtis J, Garza K, Clinton C, Yang H, Richardson A, Seals C, Hawkins G, Rose C, Nowell W, Gavigan K, Fraenkel L. Acceptance of Virtual Reality for Managing Their Disease Among People with Rheumatologic Conditions with and Without Prior Experience Using Virtual Reality [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/acceptance-of-virtual-reality-for-managing-their-disease-among-people-with-rheumatologic-conditions-with-and-without-prior-experience-using-virtual-reality/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/acceptance-of-virtual-reality-for-managing-their-disease-among-people-with-rheumatologic-conditions-with-and-without-prior-experience-using-virtual-reality/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology